What is it about?
Cardio-oncology is an emerging discipline designed to provide the most optimal oncology treatment, without compromising cardiovascular (CV) condition. In clinical practice, there are still some unmet needs, especially with regard to managing cardiotoxic effects of targeted anticancer therapy (e.g., trastuzumab, often combined with anthracycline-based chemotherapy (CHT) regimens), in patients with HER2-positive breast cancer.
Featured Image
Why is it important?
This article address easily available cardioprotective methods, such as the use of antihypertensive medications (e.g.: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs)). In addition, it underscores the role of regular monitoring of the patients’ clinical symptoms and parameters (e.g.: arterial blood pressure, heart rate, left ventricular ejection fraction (LVEF), renal functions, and cardiac biomarkers), in women with HER2-positive breast cancer..
Perspectives
To improve outcomes of many women suffering from breast cancer and CV complications, continuous collaboration between oncologists, cardiologists, primary care physicians, and patients engaged in their own care is crucial. For this reason, information about diagnostic and therapeutic strategies have to be clearly communicated to patients, to reinforce their adherence to treatment.
Katarzyna Rygiel
Read the Original
This page is a summary of: Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials, Indian Journal of Pharmacology, January 2016, Medknow,
DOI: 10.4103/0253-7613.190719.
You can read the full text:
Contributors
The following have contributed to this page
